These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 30420969

  • 21. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 22. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD, on behalf of the EDITION 3 study investigators.
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [Abstract] [Full Text] [Related]

  • 23. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis.
    Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W.
    Adv Ther; 2020 Sep; 37(9):3816-3826. PubMed ID: 32671687
    [Abstract] [Full Text] [Related]

  • 24. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
    Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM, IMAGINE 5 Investigators.
    Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
    Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
    [Abstract] [Full Text] [Related]

  • 26. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
    Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T, Kapitza C.
    Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
    [Abstract] [Full Text] [Related]

  • 27. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M, Kong X, Wang H, Zhai X, Cai T, Ding B, Hu Y, Jing T, Su X, Li H, Ma J.
    J Diabetes Res; 2020 Jul; 2020():6666403. PubMed ID: 33299890
    [Abstract] [Full Text] [Related]

  • 28. Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
    Bajaj HS, Chu L, Bansal N, Brown RE, Dhillon G, Gupta R, Bhela JS, Padda JK, Khandwala H, Venn K, Aronson R.
    Can J Diabetes; 2022 Jul; 46(5):495-502. PubMed ID: 35752566
    [Abstract] [Full Text] [Related]

  • 29. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ, Scism-Bacon JL, Zagar AJ.
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [Abstract] [Full Text] [Related]

  • 30. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, Park SW.
    PLoS One; 2014 Jul; 9(3):e87799. PubMed ID: 24614911
    [Abstract] [Full Text] [Related]

  • 31. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 32. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec 18; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Wan H, Zhao D, Shen J, Lu L, Zhang T, Chen Z.
    J Diabetes Res; 2016 Dec 18; 2016():9849328. PubMed ID: 26798658
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
    Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V, LixiLan PoC Study Group.
    Diabetes Care; 2016 Sep 18; 39(9):1579-86. PubMed ID: 27284114
    [Abstract] [Full Text] [Related]

  • 35. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC, BETA study group.
    Acta Diabetol; 2014 Apr 18; 51(2):277-85. PubMed ID: 24445656
    [Abstract] [Full Text] [Related]

  • 36. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 18; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 37. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C, Hülstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M.
    J Diabetes Complications; 2006 Oct 18; 20(3):145-52. PubMed ID: 16632233
    [Abstract] [Full Text] [Related]

  • 38. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
    Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E.
    Diabet Med; 2006 Jul 18; 23(7):736-42. PubMed ID: 16842477
    [Abstract] [Full Text] [Related]

  • 39. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B, Zhao J, Yang W, Lantus Registry Study Group.
    Diabetes Metab Res Rev; 2017 Mar 18; 33(3):. PubMed ID: 27667797
    [Abstract] [Full Text] [Related]

  • 40. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P, Malone JK.
    Diabet Med; 2006 Jul 18; 23(7):743-9. PubMed ID: 16842478
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.